MY121362A - Benzoylguanidine derivatives with advantageous properties processes for preparing them and their use in the production of pharmaceutical compositions - Google Patents

Benzoylguanidine derivatives with advantageous properties processes for preparing them and their use in the production of pharmaceutical compositions

Info

Publication number
MY121362A
MY121362A MYPI99004064A MYPI9904064A MY121362A MY 121362 A MY121362 A MY 121362A MY PI99004064 A MYPI99004064 A MY PI99004064A MY PI9904064 A MYPI9904064 A MY PI9904064A MY 121362 A MY121362 A MY 121362A
Authority
MY
Malaysia
Prior art keywords
preparing
pharmaceutical compositions
production
advantageous properties
benzoylguanidine derivatives
Prior art date
Application number
MYPI99004064A
Inventor
Christian Dr Eickmeier
Erich Dr Burger
Stefan Matthias Dr Blech
Otto Dr Roos
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY121362A publication Critical patent/MY121362A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

THE PRESENT INVENTION RELATES TO NOVEL BENZOYLGUANIDINE DERIVATIVES OF GENERAL FORMULA IPROCESSES FOR PREPARING THEM AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS.
MYPI99004064A 1998-09-22 1999-09-20 Benzoylguanidine derivatives with advantageous properties processes for preparing them and their use in the production of pharmaceutical compositions MY121362A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843489A DE19843489B4 (en) 1998-09-22 1998-09-22 Benzoylguanidine derivatives having advantageous properties, processes for their preparation and their use in the preparation of medicaments, and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
MY121362A true MY121362A (en) 2006-01-28

Family

ID=7881872

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99004064A MY121362A (en) 1998-09-22 1999-09-20 Benzoylguanidine derivatives with advantageous properties processes for preparing them and their use in the production of pharmaceutical compositions

Country Status (35)

Country Link
EP (1) EP1165534B1 (en)
JP (1) JP3817425B2 (en)
KR (1) KR100621821B1 (en)
CN (1) CN1166654C (en)
AR (1) AR023668A1 (en)
AT (1) ATE288425T1 (en)
AU (1) AU764819C (en)
BG (1) BG64985B1 (en)
BR (1) BR9913107A (en)
CA (1) CA2345006C (en)
CO (1) CO5150207A1 (en)
CZ (1) CZ300158B6 (en)
DE (2) DE19843489B4 (en)
EA (1) EA004687B1 (en)
EE (1) EE04749B1 (en)
EG (1) EG23757A (en)
ES (1) ES2237951T3 (en)
HK (1) HK1043367B (en)
HR (1) HRP20010194B1 (en)
HU (1) HU228955B1 (en)
ID (1) ID27759A (en)
IL (1) IL141805A (en)
MY (1) MY121362A (en)
NO (1) NO317993B1 (en)
NZ (1) NZ511167A (en)
PE (1) PE20001085A1 (en)
PL (1) PL195291B1 (en)
PT (1) PT1165534E (en)
RS (1) RS49971B (en)
SA (1) SA99200474B1 (en)
SK (1) SK285578B6 (en)
TR (1) TR200100801T2 (en)
TW (1) TWI221841B (en)
WO (1) WO2000017176A2 (en)
ZA (1) ZA200101212B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (en) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma New benzoylguanidine salt
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof
DE10144030A1 (en) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Composition containing 4-piperazino-benzoylguanidine derivative, useful e.g. for treating cardiac infarction, containing component to improve local tolerance, e.g. beta-cyclodextrin derivative or polymer
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
FR2871157A1 (en) * 2004-06-04 2005-12-09 Aventis Pharma Sa BIARYL AROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF
WO2010005783A1 (en) * 2008-07-08 2010-01-14 Boehringer Ingelheim International Gmbh Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (en) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Novel benzoylguanidine derivatives, process for their preparation and their use in the manufacture of medicaments

Also Published As

Publication number Publication date
ZA200101212B (en) 2002-10-04
ES2237951T3 (en) 2005-08-01
KR20010079884A (en) 2001-08-22
EE200100178A (en) 2002-10-15
PL195291B1 (en) 2007-08-31
HK1043367B (en) 2005-02-25
HUP0200225A2 (en) 2002-06-29
BR9913107A (en) 2002-06-11
PL347234A1 (en) 2002-03-25
CA2345006C (en) 2007-11-13
AU764819B2 (en) 2003-08-28
YU21501A (en) 2004-03-12
PE20001085A1 (en) 2000-10-25
TWI221841B (en) 2004-10-11
CZ20011047A3 (en) 2001-08-15
IL141805A (en) 2005-12-18
DE19843489B4 (en) 2006-12-21
EG23757A (en) 2007-08-08
SK285578B6 (en) 2007-04-05
EP1165534B1 (en) 2005-02-02
AU6465999A (en) 2000-04-10
EE04749B1 (en) 2006-12-15
CN1342153A (en) 2002-03-27
JP2002538077A (en) 2002-11-12
NO20011428L (en) 2001-03-21
SA99200474B1 (en) 2006-06-10
CO5150207A1 (en) 2002-04-29
EA200100317A1 (en) 2001-10-22
RS49971B (en) 2008-09-29
HRP20010194A2 (en) 2002-04-30
DE59911568D1 (en) 2005-03-10
PT1165534E (en) 2005-04-29
HK1043367A1 (en) 2002-09-13
CA2345006A1 (en) 2000-03-30
NZ511167A (en) 2003-12-19
BG64985B1 (en) 2006-11-30
WO2000017176A3 (en) 2001-10-11
CZ300158B6 (en) 2009-02-25
DE19843489A1 (en) 2000-03-23
WO2000017176A2 (en) 2000-03-30
ATE288425T1 (en) 2005-02-15
SK3962001A3 (en) 2001-10-08
ID27759A (en) 2001-04-26
EA004687B1 (en) 2004-06-24
KR100621821B1 (en) 2006-09-13
BG105326A (en) 2001-11-30
NO317993B1 (en) 2005-01-17
TR200100801T2 (en) 2002-04-22
NO20011428D0 (en) 2001-03-21
HRP20010194B1 (en) 2009-05-31
CN1166654C (en) 2004-09-15
JP3817425B2 (en) 2006-09-06
AU764819C (en) 2004-12-16
IL141805A0 (en) 2002-03-10
HU228955B1 (en) 2013-07-29
EP1165534A2 (en) 2002-01-02
AR023668A1 (en) 2002-09-04
HUP0200225A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
MXPA02007942A (en) Pyrrolopyrimidinone derivatives, process of preparation and use.
MY129613A (en) Cannabinoid receptor binding compounds
IL112495A0 (en) Phenylacetic acid derivatives, their preparation and compositions containing them
MX9700885A (en) New heteroaryloxazolidinones.
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
YU56302A (en) 8,8a-dihydro-indeno/1,2-d/thiazol-derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g.anorectic agents
MY115211A (en) Novel amino acid derivatives, their preparation and use
BG100069A (en) Amidine derivatives containing heterocylic groups, their preparation and application
MXPA02009643A (en) Shortened synthesis of 3,3-diarylpropylamine derivatives.
IL112020A0 (en) Arylacetic acid derivatives, their preparation and their use as fungicides
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
MXPA04002282A (en) Novel compounds and compositions as cathepsin inhibitors.
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
IL141325A0 (en) Tan-1057 derivatives
PT1427417E (en) 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents
MY121362A (en) Benzoylguanidine derivatives with advantageous properties processes for preparing them and their use in the production of pharmaceutical compositions
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
MXPA02004441A (en) Isoxazole derivatives to be used as phosphodiesterase vii inhibitors.
CA2263846A1 (en) Novel pyranoside derivatives
HUP0303319A2 (en) 9a-n[n'-(phanylsulfonyl)carbamoyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycina and of 5-o-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide a, process for their preparation and pharmaceutical compositions containing them
BG106893A (en) NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM
GB9806409D0 (en) Processes for preparing intermediates